Results 261 to 270 of about 24,516 (282)

ECULIZUMAB

Reactions Weekly, 2015
  +5 more sources

Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan

International journal of hematology, 2023
J. Nishimura, T. Kawaguchi, Shuichi Ito, H. Murai, Akihiko Shimono, Takahisa Matsuda, Yuji Fukamizu, H. Akiyama, H. Hayashi, T. Nakano, S. Maruyama   +10 more
semanticscholar   +1 more source

Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement

Pediatric nephrology (Berlin, West), 2023
D. Wildes, Susan Harvey, C. Costigan, C. Sweeney, E. Twomey, A. Awan, K. Gorman   +6 more
semanticscholar   +1 more source

Eculizumab for a catastrophic relapse in NMOSD: case report

Neurological Sciences, 2023
D. Gorriz, F. Pérez-Miralles, C. Quintanilla-Bordás, C. Alcalá, M. Frasquet, B. Casanova   +5 more
semanticscholar   +1 more source

Eculizumab

Der Nephrologe, 2012
openaire   +2 more sources

Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors

Neurological Sciences, 2023
L. Fionda, E. Rossini, Antonio Lauletta, L. Leonardi, Laura Tufano, R. Costanzo, P. Marchetti, Marco Salvetti, M. Garibaldi, S. Morino, Giovanni Antonini   +10 more
semanticscholar   +1 more source

Eculizumab

Reactions Weekly, 2017
  +4 more sources

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Nature Biotechnology, 2007
Robert A Brodsky
exaly  

Eculizumab

Reactions Weekly, 2021
openaire   +2 more sources

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

Lancet Neurology, The, 2013
Sean J Pittock, Andrew McKeon, Jay Mandrekar   +2 more
exaly